$FENC
FENNEC PHARMACEUTICALS INC.

2022 Q1 Form 10-Q Financial Statement

#000155837022008461 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.109M $2.510M
YoY Change -15.98% 2.87%
% of Gross Profit
Research & Development $1.437M $2.416M
YoY Change -40.52% 73.81%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.437M $2.416M
YoY Change -40.52% -37.08%
Operating Profit -$3.546M -$4.923M
YoY Change -27.97%
Interest Expense -$150.0K $200.0K
YoY Change -175.0% 900.0%
% of Operating Profit
Other Income/Expense, Net -$150.0K $190.0K
YoY Change -178.95% -2000.0%
Pretax Income -$3.696M -$4.730M
YoY Change -21.86% 23.5%
Income Tax
% Of Pretax Income
Net Earnings -$3.696M -$4.733M
YoY Change -21.91% 23.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.18
Diluted Earnings Per Share -$0.14 -$0.18
COMMON SHARES
Basic Shares Outstanding 26.02M 26.00M
Diluted Shares Outstanding 26.02M 26.00M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.26M $26.75M
YoY Change -31.74% 170.2%
Cash & Equivalents $18.26M $26.75M
Short-Term Investments
Other Short-Term Assets $154.0K $1.080M
YoY Change -85.74% 390.91%
Inventory
Prepaid Expenses $715.0K
Receivables
Other Receivables
Total Short-Term Assets $19.13M $27.83M
YoY Change -31.27% 175.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K
YoY Change
Total Long-Term Assets $21.00K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $19.13M $27.83M
Total Long-Term Assets $21.00K $0.00
Total Assets $19.15M $27.83M
YoY Change -31.19% 168.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.224M $2.510M
YoY Change -51.24% 49.4%
Accrued Expenses $412.0K $380.0K
YoY Change 8.42% 65.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K
YoY Change
Total Short-Term Liabilities $2.136M $2.890M
YoY Change -26.09% 51.31%
LONG-TERM LIABILITIES
Long-Term Debt $4.500M $0.00
YoY Change
Other Long-Term Liabilities -$11.00K
YoY Change
Total Long-Term Liabilities $4.489M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.136M $2.890M
Total Long-Term Liabilities $4.489M $0.00
Total Liabilities $6.625M $2.890M
YoY Change 129.24% 51.31%
SHAREHOLDERS EQUITY
Retained Earnings -$183.2M
YoY Change
Common Stock $194.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.52M $24.93M
YoY Change
Total Liabilities & Shareholders Equity $19.15M $27.83M
YoY Change -31.19% 168.37%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.696M -$4.733M
YoY Change -21.91% 23.71%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.856M -$3.593M
YoY Change -20.51% -4.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00K
YoY Change
NET CHANGE
Cash From Operating Activities -2.856M -3.593M
Cash From Investing Activities
Cash From Financing Activities 15.00K
Net Change In Cash -2.841M -3.593M
YoY Change -20.93% -4.19%
FREE CASH FLOW
Cash From Operating Activities -$2.856M -$3.593M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Trading Symbol
TradingSymbol
FENCF
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001211583
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 fenc Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q1 fenc Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26040000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26014000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-32295
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CA
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0442384
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 13628, 68 TW Alexander Drive
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Research Triangle Park
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27709
CY2022Q1 dei City Area Code
CityAreaCode
919
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
636-4530
CY2022Q1 dei Security12b Title
Security12bTitle
Common Shares, no par value
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26039444
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18259000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21100000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
715000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1034000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
154000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
253000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
19128000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
22387000
CY2022Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
21000
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
27000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
21000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
27000
CY2022Q1 us-gaap Assets
Assets
19149000
CY2021Q4 us-gaap Assets
Assets
22414000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1224000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
777000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
412000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
877000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
500000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2136000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1654000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4500000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
12000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4489000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4988000
CY2022Q1 us-gaap Liabilities
Liabilities
6625000
CY2021Q4 us-gaap Liabilities
Liabilities
6642000
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26040000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26014000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
140832000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
140801000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
53631000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
53214000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183182000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179486000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12524000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15772000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19149000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22414000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1437000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2416000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2109000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2507000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3546000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4923000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-4000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7000
CY2022Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-91000
CY2021Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
182000
CY2022Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
9000
CY2021Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
16000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
58000
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-150000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
190000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3696000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4733000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26019000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26003000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26019000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26003000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3696000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4733000
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1000
CY2022Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-91000
CY2021Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
182000
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
34000
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
9000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
399000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
587000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-319000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-178000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
447000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
937000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-465000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-392000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2856000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3593000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2841000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3593000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21100000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30344000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18259000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26751000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15772000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3696000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12524000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29070000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4733000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
24933000
CY2022Q1 fenc Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
4
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3546000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183182000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2856000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at March 31, 2022 and to state fairly the results for the periods presented. The most significant estimates utilized during the three months ended March 31, 2022 include estimates necessary to value grants of stock options to employees and various contractors, as disclosed in Note 4.</p>
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18259000
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18259000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21100000
CY2022Q1 us-gaap Cash
Cash
131000
CY2022Q1 us-gaap Cash
Cash
39000
CY2021Q4 us-gaap Cash
Cash
34000
CY2022Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q3 fenc Royalties Percentage
RoyaltiesPercentage
0.05
CY2022Q1 fenc Royalties Percentage
RoyaltiesPercentage
0.05
CY2020 us-gaap Revenues
Revenues
200000
CY2022Q1 fenc Collaborative Arrangement Liquidity Discount Percentage
CollaborativeArrangementLiquidityDiscountPercentage
0.20
CY2022Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-91000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-17000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3696000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4733000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26019000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26003000
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26019000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26003000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q1 fenc Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2022Q1 fenc Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39000
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.80
CY2022Q1 fenc Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2022Q1 fenc Exercise Price Of Warrants Issued
ExercisePriceOfWarrantsIssued
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39000
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.80
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18259000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21100000
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
433000
CY2021Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
596000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
148000
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
240000
CY2020Q4 us-gaap Share Price
SharePrice
4.11
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000
CY2020Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
2000

Files In Submission

Name View Source Status
0001558370-22-008461-index-headers.html Edgar Link pending
0001558370-22-008461-index.html Edgar Link pending
0001558370-22-008461.txt Edgar Link pending
0001558370-22-008461-xbrl.zip Edgar Link pending
fencf-20220331.xsd Edgar Link pending
fencf-20220331x10q.htm Edgar Link pending
fencf-20220331x10q002.jpg Edgar Link pending
fencf-20220331x10q_htm.xml Edgar Link completed
fencf-20220331xex31d1.htm Edgar Link pending
fencf-20220331xex31d2.htm Edgar Link pending
fencf-20220331xex32d1.htm Edgar Link pending
fencf-20220331xex99d1.htm Edgar Link pending
fencf-20220331xex99d1001.jpg Edgar Link pending
fencf-20220331_cal.xml Edgar Link unprocessable
fencf-20220331_def.xml Edgar Link unprocessable
fencf-20220331_lab.xml Edgar Link unprocessable
fencf-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending